Literature DB >> 20144930

Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome.

Eric Hachulla1, David Launay, Azzedine Yaici, Alice Berezne, Pascal de Groote, Olivier Sitbon, Luc Mouthon, Loïc Guillevin, Pierre-Yves Hatron, Gérald Simonneau, Pierre Clerson, Marc Humbert.   

Abstract

OBJECTIVE: To describe the history of SSc-associated pulmonary arterial hypertension (SSc-PAH) in patients with New York Heart Association (NYHA) functional class (FC) II dyspnoea at diagnosis.
METHODS: Data at the time of diagnosis were collected and analysed retrospectively for 77 consecutive patients with SSc-PAH.
RESULTS: Twelve patients (15.6%) presented with PAH and NYHA FC II dyspnoea. After a mean follow-up of 44 months, only 4 out of the 12 PAH patients remained stable in FC II, while 8 showed worsening to FC III or IV. Three patients died during the observation period; two from PAH and one from rectal cancer. Survival in patients in FC II at diagnosis was 100, 91 and 80% at 1, 2 and 3 years, respectively.
CONCLUSIONS: A majority of patients with mildly symptomatic SSc-PAH in NYHA FC II at diagnosis have a severe disease with poor prognosis.

Entities:  

Mesh:

Year:  2010        PMID: 20144930     DOI: 10.1093/rheumatology/kep449

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  17 in total

1.  Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension.

Authors:  Masaru Hatano; Hidehiro Yamada; Keiichi Fukuda; Koichiro Yoshioka; Masanori Funauchi; Masataka Kuwana; Masataka Sata; Mitsugu Taniguchi; Norifumi Nakanishi; Takefumi Saito; Tsutomu Saji; Shigetake Sasayama
Journal:  Heart Vessels       Date:  2014-07-16       Impact factor: 2.037

2.  Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis.

Authors:  Edward A Pankey; Matthew Epps; Bobby D Nossaman; Albert L Hyman; Philip J Kadowitz
Journal:  J Clin Rheumatol Musculoskelet Med       Date:  2010-12-01

3.  Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension.

Authors:  Yoshiaki Furuya; Toru Satoh; Masataka Kuwana
Journal:  Int J Rheumatol       Date:  2010-08-02

4.  Unique Abnormalities in Right Ventricular Longitudinal Strain in Systemic Sclerosis Patients.

Authors:  Monica Mukherjee; Shang-En Chung; Von Khue Ton; Ryan J Tedford; Laura K Hummers; Fredrick M Wigley; Theodore P Abraham; Ami A Shah
Journal:  Circ Cardiovasc Imaging       Date:  2016-06-07       Impact factor: 7.792

5.  Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS).

Authors:  Kathleen D Kolstad; Shufeng Li; Virginia Steen; Lorinda Chung
Journal:  Chest       Date:  2018-05-16       Impact factor: 9.410

Review 6.  The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients.

Authors:  Barbara Ruaro; Marco Confalonieri; Francesco Salton; Barbara Wade; Elisa Baratella; Pietro Geri; Paola Confalonieri; Metka Kodric; Marco Biolo; Cosimo Bruni
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-23

7.  Exercise training in pulmonary arterial hypertension associated with connective tissue diseases.

Authors:  Ekkehard Grünig; Felicitas Maier; Nicola Ehlken; Christine Fischer; Mona Lichtblau; Norbert Blank; Christoph Fiehn; Frank Stöckl; Felix Prange; Gerd Staehler; Frank Reichenberger; Henning Tiede; Michael Halank; Hans-Jürgen Seyfarth; Simone Wagner; Christian Nagel
Journal:  Arthritis Res Ther       Date:  2012-06-18       Impact factor: 5.156

8.  N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.

Authors:  Vivek Thakkar; Wendy M Stevens; David Prior; Owen A Moore; Jillian Byron; Danny Liew; Karen Patterson; Pravin Hissaria; Janet Roddy; Jane Zochling; Joanne Sahhar; Peter Nash; Kathleen Tymms; David Celermajer; Eli Gabbay; Peter Youssef; Susanna M Proudman; Mandana Nikpour
Journal:  Arthritis Res Ther       Date:  2012-06-12       Impact factor: 5.156

9.  In search of markers of treatment failure and poor prognosis in IPAH - the value of mosaic lung attenuation pattern on thin-section CT scans.

Authors:  Monika Szturmowicz; Aneta Kacprzak; Barbara Burakowska; Marcin Kurzyna; Anna Fijałkowska; Iwona Bestry; Adam Torbicki
Journal:  Multidiscip Respir Med       Date:  2010-12-20

10.  Pulmonary hypertension in parenchymal lung disease.

Authors:  Iraklis Tsangaris; Georgios Tsaknis; Anastasia Anthi; Stylianos E Orfanos
Journal:  Pulm Med       Date:  2012-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.